Pilot liquid emulsion for asthma
This article was originally published in The Tan Sheet
Airozin medical food for dietary maintenance of asthma is slated to launch April 7 at supermarkets, drugstores in the Carolinas, Pilot says. AC Nielsen will test direct and retail marketing to gauge success, firm notes. Airozin launch has been postponed twice, most recently due to flavor reformulation; product now is a mint, rather than citrus-flavored, liquid emulsion. Previously, the Charleston, S.C.-based firm delayed launch plans while awaiting the completion of clinical trials supporting product's efficacy (1"The Tan Sheet" Nov. 4, 2002, p. 16). Two studies, one on Airozin's safety and pharmacokinetics, are slated for publication in the March Clinical Therapeutics. Firm is sponsoring Charleston Asthma Summit April 10 to educate physicians, pharmacists, advocacy groups on asthma management...
You may also be interested in...
Pilot Therapeutics plans to introduce its asthma maintenance therapy, Airozin, by the end of 2002 after a six-month delay, the company said
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.